Cretostimogene grenadenorepvec
Highest phase reached
Phase 3
Drug type
Gene
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Gene
- Drug name
- Cretostimogene grenadenorepvec
- cg 0070
- CG 0070
- CG-0070
- cg0070
- CG0070
- CG0070 GENOME STRUCTURE COMPRISES A LEFT ITR (5' ITR), A POLYA SEQUENCE, AN E2F RESPONSIVE PROMOTER LINKED TO THE ADENOVIRAL E1A CODING REGION, A HETEROLOGOUS CODING SEQUENCE ENCODING GM-CSF, AND A RIGHT ITR (3' ITR) AND CARRIES MOST OF THE WILD-TYPE HUMAN ADENOVIRUS AD5 GENOME (GENBANK: AY339865.1), EXCEPT FOR THE FOLLOWING REGIONS: (1) THE ENDOGENOUS PROMOTER OF THE ESSENTIAL EARLY GENE E1A HAS BEEN REPLACED BY HUMAN E2F-1 PROMOTER (GENBANK ACCESSION NO. AF516106.1), (2) A SV40 LATE POLYADENYLATION SIGNAL HAS BEEN PLACED UPSTREAM TO THE HE2F-1 PROMOTER, AND (3) E3 GP19KD-CODING REGION HAS BEEN REPLACED BY HUMAN GM-CSF CDNA SEQUENCE (ACCESSION NO. NM_000758.3)
- cg0070 genome structure comprises a left itr 5 itr a polya sequence an e2f responsive promoter linked to the adenoviral e1a coding region a heterologous coding sequence encoding gm csf and a right itr 3 itr and carries most of the wild type human adenovirus ad5 genome genbank ay339865 1 except for the following regions 1 the endogenous promoter of the essential early gene e1a has been replaced by human e2f 1 promoter genbank accession no af516106 1 2 a sv40 late polyadenylation signal has been placed upstream to the he2f 1 promoter and 3 e3 gp19kd coding region has been replaced by human gm csf cdna sequence accession no nm 000758 3
- cretostimogen grenadenorepvec
- Cretostimogen grenadenorepvec
- cretostimogene grenadenorepvec
- Cretostimogene grenadenorepvec
- Cretostimogene Grenadenorepvec
- cretostimogene grenadenorepvec [INN]
- CRETOSTIMOGENE GRENADENOREPVEC [USAN]
- Cretostimogene grenadenorepvec [WHO-DD]
- cretostimogene grenadenorepvec inn
- cretostimogene grenadenorepvec usan
- cretostimogene grenadenorepvec who dd
- CAS registry numbers
- 2414312-87-9
- ChEMBL ID
- CHEMBL5095454
- FDA ingredient codes (UNII)
- THP9ML4NTZ
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- Yes
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Urinary Bladder Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0001187
- Subject identifier
- D001749
- Condition
- Urinary Bladder Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004986
- Subject identifier
- D001749
- Condition identifier
- EFO_0000616
- Condition identifier
- MONDO_0001187
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0001187
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004647
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004986
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005611
- Highest recorded phase
- 1
- NCT02365818
- NCT04387461
- NCT06253845
- NCT04610671
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (10)
- A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
- An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG
- Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
- Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
- Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure
- Study of CG0070 After Transurethral Resection in Patients With IR NMIBC
- Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC
- Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin
- Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
- Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
In development for (3)
- Neoplasm Phase 1
- Urinary bladder cancer Phase 2
- Urinary bladder carcinoma Phase 2